- Home
- CLRB vs LGVN Comparison
CLRB vs LGVN Comparison
Compare CLRB & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- LGVN
- Stock Information
- Founded
- CLRB 2002
- LGVN 2014
- Country
- CLRB United States
- LGVN United States
- Employees
- CLRB N/A
- LGVN N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CLRB Health Care
- LGVN Health Care
- Exchange
- CLRB Nasdaq
- LGVN Nasdaq
- Market Cap
- CLRB 17.5M
- LGVN 16.4M
- IPO Year
- CLRB N/A
- LGVN 2021
- Fundamental
- Price
- CLRB $4.97
- LGVN $0.80
- Analyst Decision
- CLRB Hold
- LGVN Strong Buy
- Analyst Count
- CLRB 2
- LGVN 2
- Target Price
- CLRB N/A
- LGVN $6.50
- AVG Volume (30 Days)
- CLRB 110.6K
- LGVN 462.9K
- Earning Date
- CLRB 11-17-2025
- LGVN 11-11-2025
- Dividend Yield
- CLRB N/A
- LGVN N/A
- EPS Growth
- CLRB N/A
- LGVN N/A
- EPS
- CLRB N/A
- LGVN N/A
- Revenue
- CLRB N/A
- LGVN $2,073,000.00
- Revenue This Year
- CLRB N/A
- LGVN N/A
- Revenue Next Year
- CLRB N/A
- LGVN N/A
- P/E Ratio
- CLRB N/A
- LGVN N/A
- Revenue Growth
- CLRB N/A
- LGVN 68.67
- 52 Week Low
- CLRB $4.11
- LGVN $0.63
- 52 Week High
- CLRB $66.00
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- CLRB 45.44
- LGVN 46.18
- Support Level
- CLRB $4.56
- LGVN $0.78
- Resistance Level
- CLRB $4.98
- LGVN $0.99
- Average True Range (ATR)
- CLRB 0.35
- LGVN 0.05
- MACD
- CLRB -0.13
- LGVN 0.02
- Stochastic Oscillator
- CLRB 18.11
- LGVN 26.87
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.